Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What CAGR Is Anticipated for the Parathyroid Disease Treatment Market Through 2029?

The market scale for the treatment of parathyroid diseases has seen significant expansion in the recent past. The market was valued at $2.21 billion in 2024 and is forecasted to reach $2.37 billion by 2025, indicating a compound annual growth rate (CAGR) of 7.2%. The past growth can be linked to a rise in chronic kidney disease cases, increase in osteoporosis diagnoses, heightened awareness about endocrine disorders, broadening of diagnostic abilities, and enhanced access to specialty healthcare facilities.

In the coming years, the market for parathyroid disease treatment is projected to experience robust growth. The market is set to expand to $3.10 billion by 2029, with a compound annual growth rate (CAGR) of 7.0%. This projected expansion within the forecasted period can be credited to various factors such as an increasing aged population, the escalating use of non-surgical treatments, the rising occurrence of bone disorders post menopause, government action plans for the management of rare diseases, and a growing preference for minimally invasive parathyroidectomy. Furthermore, the market will be marked with key trends within this forecasted period such as a movement towards individualized hormone therapies, the rise of long-acting hormone analogs, the implementation of AI in endocrine diagnostics, efforts towards calcium-sensing receptor targeted drugs, and progress in parathyroid hormone analogs.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25866&type=smp

What Market Forces Are Driving The Parathyroid Disease Treatment Sector In 2025 And Beyond?

The escalating occurrence of chronic kidney disease (CKD) is predicted to boost the expansion of the parathyroid disease treatment market. CKD is a persistent ailment in which there is a slow deterioration in kidney function, causing disruptions in mineral balance such as calcium and phosphorus. The main cause of CKD’s escalating occurrence is the growing number of diabetes cases, because consistently elevated blood sugar levels can harm the kidney’s filtration units over time, resulting in diabetic nephropathy. Parathyroid disease treatment plays a crucial role in the management of CKD by addressing secondary hyperparathyroidism, a common complication in progressive CKD that interferes with calcium and phosphorus equilibrium, results in bone disease, and encourages vascular calcification. For example, in June 2024, the Australian Institute of Health and Welfare, a government agency in Australia, reported that chronic kidney disease mortality rates increased by 4.2% in 2021 and by 6.2% in 2022. Moreover, in 2022, CKD was responsible for approximately 22,000 deaths, comprising 11% of all deaths in Australia, with a mortality rate of 84 per 100,000 population. Hence, the escalating occurrence of chronic kidney disease is stimulating the growth of the parathyroid disease treatment market.

How Is The Global Parathyroid Disease Treatment Market Categorized By Segments?

The parathyroid disease treatment market covered in this report is segmented –

1) By Treatment: Calcimimetics, Bisphosphonates, Plicamycin, Hormone Replacement Therapy, Other Treatments

2) By Route Of Administration: Oral, Parenteral

3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

4) By End-Users: Hospitals, Homecare, Specialty Centers, Other End-Users

Subsegments:

1) By Calcimimetics: Cinacalcet, Etelcalcetide

2) By Bisphosphonates: Alendronate, Ibandronate, Risedronate, Zoledronic Acid

3) By Plicamycin: Mithramycin (Plicamycin) Monotherapy, Combination Therapies Involving Plicamycin

4) By Hormone Replacement Therapy: Estrogen Therapy, Progesterone Therapy, Combined Hormonal Therapies, Selective Estrogen Receptor Modulators (SERMs)

5) By Other Treatments: Parathyroid Hormone (PTH) Analogues, Surgery (Parathyroidectomy), Dietary Supplements, Lifestyle And Nutritional Interventions

How Are Key Trends Driving Expansion In The Parathyroid Disease Treatment Industry?

In the parathyroid disease treatment market, leading corporations are zeroing in on the creation of groundbreaking products such as parathyroid hormone prodrugs. These help bolster calcium regulation and dwindle the need for frequent dosage in hypoparathyroidism sufferers. Parathyroid hormone (PTH) prodrugs – inactive substances that transform into active PTH within the body – are used to maintain calcium and phosphate equilibrium. For instance, Ascendis Pharma A/S, a biopharmaceutical company based in Denmark, gained the green light from the US Food and Drug Administration (FDA) in August 2024 for YORVIPATH (palopegteriparatide). This PTH (PTH[1-34]) prodrug is an innovative treatment for chronic hypoparathyroidism in adults. This therapy, applied once daily, offers a consistent supply of parathyroid hormone over the course of 24 hours. It presents a substitute to traditional calcium and vitamin D supplementing by directly addressing the hormone deficit. The endorsement of YORVIPATH highlights the growing focus on state-of-the-art hormone replacement treatments, aiming to improve patient compliance and secure superior clinical outcomes for individuals with parathyroid anomalies.

Which Firms Are Considered Leaders In The Parathyroid Disease Treatment Market Space?

Major companies operating in the parathyroid disease treatment market are AstraZeneca PLC, Amgen Inc., Teijin Pharma Limited, Kyowa Kirin Co. Ltd., Shandong Buchang Pharmaceuticals Co. Ltd., OPKO Health Inc., Septerna Inc., Entera Bio Ltd., Visen Pharmaceuticals (Shanghai) Co. Ltd., Ascendis Pharma A/S, Aeterna Zentaris Inc., MBX Biosciences Inc., STERIS Healthcare Private Limited (subsidiary of STERIS plc), Crinetics Pharmaceuticals Inc., Amorphical Ltd., Vidasym Inc., Extend Biosciences Inc., Rani Therapeutics LLC, Pathalys Pharma Inc., ProLynx LLC.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/parathyroid-disease-treatment-global-market-report

What Role Do Regional Policies And Investments Play In Parathyroid Disease Treatment Market Expansion?

Asia-Pacific was the largest region in the parathyroid disease treatment market in 2024. The regions covered in the parathyroid disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=25866&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model